Unstable angina / non ST elevation myocardial infarction ACC/AHA guidelines for anticoagulation therapy: Difference between revisions

Acute Coronary Syndrome Main Page
	Unstable angina / NSTEMI Microchapters
Home
Patient Information
Overview
Classification
Pathophysiology
Unstable Angina
Non-ST Elevation Myocardial Infarction
Differentiating Unstable Angina/Non-ST Elevation Myocardial Infarction from other Disorders
Epidemiology and Demographics
Risk Stratification
Natural History, Complications and Prognosis
Special Groups
Women
Heart Failure and Cardiogenic Shock
Perioperative NSTE-ACS Related to Noncardiac Surgery
Stress (Takotsubo) Cardiomyopathy
Diabetes Mellitus
Post CABG Patients
Older Adults
Chronic Kidney Disease
Angiographically Normal Coronary Arteries
Variant (Prinzmetal's) Angina
Substance Abuse
Cardiovascular "Syndrome X"
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Blood Studies
Biomarkers
Electrocardiogram
Chest X Ray
Echocardiography
Coronary Angiography
Treatment
Primary Prevention
Immediate Management
Anti-Ischemic and Analgesic Therapy
Cholesterol Management
Antitplatelet Therapy
Antiplatelet therapy recommendations
Aspirin
Thienopyridines
Glycoprotein IIb/IIIa Inhibitor
Anticoagulant Therapy
Additional Management Considerations for Antiplatelet and Anticoagulant Therapy
Risk Stratification Before Discharge for Patients With an Ischemia-Guided Strategy of NSTE-ACS
Mechanical Reperfusion
Initial Conservative Versus Initial Invasive Strategies
PCI
CABG
Complications of Bleeding and Transfusion
Discharge Care
Medical Regimen
Post-Discharge Follow-Up
Cardiac Rehabilitation
Long-Term Medical Therapy and Secondary Prevention
ICD implantation within 40 days of myocardial infarction
ICD within 90 days of revascularization
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Unstable angina / non ST elevation myocardial infarction ACC/AHA guidelines for anticoagulation therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Unstable angina / non ST elevation myocardial infarction ACC/AHA guidelines for anticoagulation therapy
CDC onUnstable angina / non ST elevation myocardial infarction ACC/AHA guidelines for anticoagulation therapy
Unstable angina / non ST elevation myocardial infarction ACC/AHA guidelines for anticoagulation therapy in the news
Blogs on Unstable angina / non ST elevation myocardial infarction ACC/AHA guidelines for anticoagulation therapy
to Hospitals Treating Unstable angina / non ST elevation myocardial infarction ACC/AHA guidelines for anticoagulation therapy
Risk calculators and risk factors for Unstable angina / non ST elevation myocardial infarction ACC/AHA guidelines for anticoagulation therapy

← Older edit Newer edit →

VisualWikitext

Revision as of 20:59, 31 October 2012

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editors-in-Chief: Varun Kumar, M.B.B.S.; Lakshmi Gopalakrishnan, M.B.B.S.; Smita Kohli, M.D.

ACC / AHA Guidelines for Anticoagulation Therapy (DO NOT EDIT)

Class I
"1. Anticoagulant therapy should be added to antiplatelet therapy in UA / NSTEMI patients as soon as possible after presentation. a) For patients in whom an invasive strategy is selected, regimens with established efficacy at a (Level of Evidence: A) include enoxaparin and UFH, and those with established efficacy at a (Level of Evidence: B) include bivalirudin and fondaparinux. b) For patients in whom a conservative strategy is selected, regimens using either enoxaparin or UFH (Level of Evidence: A) or fondaparinux (Level of Evidence: B) have established efficacy. c) In patients in whom a conservative strategy is selected and who have an increased risk of bleeding, fondaparinux is preferable. (Level of Evidence: B) "

Class IIa
"1. For UA / NSTEMI patients in whom an initial conservative strategy is selected, enoxaparin or fondaparinux is preferable to UFH as anticoagulant therapy, unless CABG is planned within 24 h. (Level of Evidence: B)"

Sources

The ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction ^[1]

References

↑ Anderson JL, Adams CD, Antman EM; et al. (2007). "ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine". JACC. 50 (7): e1–e157. PMID 17692738. Text "doi:10.1016/j.jacc.2007.02.013 " ignored (help); Unknown parameter |month= ignored (help)

Template:WH Template:WS

[pmid17692738-1] Anderson JL, Adams CD, Antman EM; et al. (2007). "ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine". JACC. 50 (7): e1–e157. PMID 17692738. Text "doi:10.1016/j.jacc.2007.02.013 " ignored (help); Unknown parameter |month= ignored (help)

[1]

@@ Line 5: / Line 5: @@
 ==ACC / AHA Guidelines for Anticoagulation Therapy (DO NOT EDIT)==
-{{cquote|
+{|class="wikitable"
-===Class I===
+|-
+| colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]]
+|-
+| bgcolor="LightGreen"|
+<nowiki>"</nowiki>'''1.''' Anticoagulant therapy should be added to [[antiplatelet therapy]] in [[UA]] / [[NSTEMI]] patients as soon as possible after presentation.
-'''1.''' Anticoagulant therapy should be added to [[antiplatelet therapy]] in [[UA]] / [[NSTEMI]] patients as soon as possible after presentation.
+:'''a)''' For patients in whom an invasive strategy is selected, regimens with established efficacy at a ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])'' include [[enoxaparin]] and [[UFH]], and those with established efficacy at a ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])'' include [[bivalirudin]] and [[fondaparinux]].
-::'''a.''' For patients in whom an invasive strategy is selected, regimens with established efficacy at a ''Level of Evidence: A'' include [[enoxaparin]] and [[UFH]], and those with established efficacy at a ''Level of Evidence: B'' include [[bivalirudin]] and [[fondaparinux]].
-::'''b.''' For patients in whom a conservative strategy is selected, regimens using either [[enoxaparin]] or [[UFH]] ''(Level of Evidence: A)'' or [[fondaparinux]] ''(Level of Evidence: B)'' have established efficacy.
-::'''c.''' In patients in whom a conservative strategy is selected and who have an increased risk of bleeding, [[fondaparinux]] is preferable. ''(Level of Evidence: B)''
-===Class IIa===
+:'''b)''' For patients in whom a conservative strategy is selected, regimens using either [[enoxaparin]] or [[UFH]] ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])'' or [[fondaparinux]] ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])'' have established efficacy.
-'''1.''' For [[UA]] / [[NSTEMI]] patients in whom an initial conservative strategy is selected, [[enoxaparin]] or [[fondaparinux]] is preferable to [[UFH]] as [[anticoagulant therapy]], unless [[CABG]] is planned within 24 h. ''(Level of Evidence: B)''}}
+:'''c)''' In patients in whom a conservative strategy is selected and who have an increased risk of bleeding, [[fondaparinux]] is preferable. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])'' <nowiki>"</nowiki>
+|}
+{|class="wikitable"
+|-
+| colspan="1" style="text-align:center; background:LemonChiffon"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]]
+|-
+| bgcolor="LemonChiffon"|
+<nowiki>"</nowiki>'''1.''' For [[UA]] / [[NSTEMI]] patients in whom an initial conservative strategy is selected, [[enoxaparin]] or [[fondaparinux]] is preferable to [[UFH]] as [[anticoagulant therapy]], unless [[CABG]] is planned within 24 h. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki>
+|}
 ==See Also==

Unstable angina / non ST elevation myocardial infarction ACC/AHA guidelines for anticoagulation therapy: Difference between revisions

Revision as of 20:59, 31 October 2012

ACC / AHA Guidelines for Anticoagulation Therapy (DO NOT EDIT)

See Also

Sources

References

Navigation menu

Search